TXG
10x Genomics, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$62.65
−0.90%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 616.9M | 642.8M | 610.8M | 618.7M | 516.4M |
| Cost of Revenue | 184.9M | 198.9M | 196.3M | 209.4M | 120.4M |
| Gross Profit | 432.0M | 443.9M | 414.5M | 409.3M | 396.0M |
| Operating Expenses | |||||
| R&D Expense | 226.8M | 238.6M | 264.7M | 270.3M | 265.7M |
| SG&A Expense | 297.0M | 316.1M | 344.3M | 343.3M | 298.3M |
| General & Admin Expense | — | — | 340.4M | — | 294.6M |
| Selling & Marketing Expense | — | — | 3.9M | — | 3.7M |
| Other Expenses | (3.4M) | — | — | 61.0M | — |
| Total Operating Expenses | 520.4M | 554.8M | 609.0M | 674.6M | 564.0M |
| Cost and Expenses | 705.3M | 753.7M | 805.3M | 884.1M | 684.4M |
| Operating Income (EBIT) | (88.4M) | (110.9M) | (194.6M) | (265.3M) | (167.9M) |
| Non-Operating | |||||
| Interest Income | 20.5M | 20.0M | 18.4M | 16.9M | 6.6M |
| Interest Expense | 3.0K | — | 4.0K | 33.0K | 476.0K |
| Net Interest Income | 20.5M | 20.0M | 18.4M | 16.9M | 6.2M |
| Other Non-Op Income/Expense | 13.5M | 71.0M | 16.9M | 16.6M | 6.0M |
| Non-Operating Income (excl Interest) | (80.1M) | (71.0M) | (16.9M) | (16.6M) | (6.4M) |
| EBT (Pre-Tax Income) | (74.9M) | (39.9M) | (177.7M) | (248.8M) | (162.0M) |
| Income Tax Expense | 235.0K | 3.6M | 4.9M | 6.3M | 4.0M |
| Bottom Line | |||||
| Net Income | (75.1M) | (43.5M) | (182.6M) | (255.1M) | (166.0M) |
| Earnings from Cont. Ops | (75.1M) | (43.5M) | (182.6M) | (255.1M) | (166.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (75.1M) | (43.5M) | (182.6M) | (255.1M) | (166.0M) |
| Per Share | |||||
| Basic EPS | ($0.59) | ($0.35) | ($1.52) | ($2.18) | ($1.46) |
| Diluted EPS | ($0.59) | ($0.35) | ($1.52) | ($2.18) | ($1.46) |
| Revenue Per Share | $4.75 | $5.15 | $5.07 | $5.28 | $4.54 |
| Shares | |||||
| Basic Shares Outstanding | 130.0M | 124.7M | 120.5M | 117.2M | 113.9M |
| Diluted Shares Outstanding | 130.0M | 124.7M | 120.5M | 117.2M | 113.9M |
| Profitability Metrics | |||||
| EBITDA | 28.0M | 3.9M | (134.0M) | (205.1M) | (128.5M) |
| D&A | 36.3M | 43.8M | 43.7M | 43.6M | 33.0M |
| EBIT | (8.3M) | (39.9M) | (177.7M) | (248.7M) | (161.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026